Epigenetics Therapeutics to 2017 High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma - GBI Research Reports

Epigenetics Therapeutics to 2017 High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

Epigenetics Therapeutics to 2017 High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma - GBI Research Reports
Epigenetics Therapeutics to 2017 High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma
Published Sep 01, 2010
89 pages — Published Sep 01, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Researchs report, Epigenetics Therapeutics to 2017 High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma, provides in-depth analysis of trends, issues and challenges in this industry. The report analyzes the technology that shape the industry dynamics for the key geographies: the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Further, the report provides competitive benchmarking for the leading companies and analyzes the licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

Scope

The scope of this report includes -
- Annualized market data from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading technology in this space
- Analysis of the leading technology in this space
- Market characterization
- Key drivers and barriers that have a significant impact on the market.
- Competitive benchmarking of leading companies.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

  
Source:
Document ID
GBIHC039MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents34
  List of Tables51
  List of Figures61
Introduction71
  GBI Research Report Guidance71
Market Characterization: Global Epigenetics Market88
  Disease Overview81
    Myelodysplastic Syndrome81
    Cutaneous T-cell Lymphoma81
  Epigenetic Drugs92
  The US111
  Top Five European Markets122
  Japan142
In-Depth Analysis1659
  Introduction161
  Vidaza (Azacitidine)161
    Indication161
    Mechanism of Action161
    Revenue Forecast161
      Global172
      The US191
      Europe202
      Japan221
    Key Takeaway231
    Market Potential231
      Global233
      The US261
      Europe271
      Japan281
    Key Takeaway291
    Pipeline Analysis291
      Clinical Studies by Phase291
      Clinical Studies by Indication301
    Key takeaway311
    Drug Profile321
      Overview321
      Dosage321
      Price321
      Safety321
      Efficacy321
      Clinical Studies331
  Dacogen (Decitabine)331
    Indication331
    Mechanism of action331
    Revenue Forecast341
      Global342
      The US361
      The Top 5 European countries371
      Japan381
    Key Takeaway391
    Market Potential391
      Global393
      The US421
      Europe431
      Japan441
    Key Takeaway451
    Pipeline Analysis451
      Clinical Studies by Phase451
      Clinical Studies by Indication461
    Key Takeaway471
    Drug Profile481
      Overview481
      Dosage481
      Price481
      Safety481
      Efficacy481
      Clinical Studies481
  Zolinza (Vorinostat)491
    Indication491
    Mechanism of Action491
    Revenue Forecast491
      Global502
      The US521
      Europe531
      Japan541
    Key Takeaway551
    Disease Overview551
      Multiple Myeloma551
    Market Potential551
      Global553
      The US581
      Europe591
      Japan601
    Key Takeaway611
    Pipeline Analysis611
      Clinical Studies by Phase611
      Clinical Studies by Indication621
    Key Takeaway631
    Drug Profile631
      Overview631
      Dosage631
      Price641
      Safety641
      Efficacy641
      Clinical Studies641
  Istodax (Romidepsin)641
    Indication641
    Disease Overview641
      Cutaneous T-cell lymphoma641
    Mechanism of Action651
    Market Potential651
      Global653
      The US681
      Europe691
      Japan701
    Key Takeaway711
    Pipeline Analysis711
    Clinical Studies by Phases711
    Clinical Studies by Indication721
    Key Takeaway731
    Drug Profile731
      Overview731
      Dosage731
      Price731
      Safety741
      Efficacy741
      Clinical Studies741
Competitive Landscape758
  Merck &Co.751
    Company Overview751
    Business Description751
      Overview752
    SWOT771
      Overview771
  Celgene Corporation771
    Company Overview771
      Financial Performance771
    Business Description781
      Overview781
    SWOT791
      Overview791
  EISAI801
    Company Overview801
    Business Description801
      Overview802
    SWOT821
      Overview821
Epigenetic Therapeutics: Appendix837
  Market Definitions831
  Abbreviations831
  Research Methodology845
    Coverage851
    Secondary Research851
    Primary Research851
    Forecasts861
      Epidemiology-based Forecasting862
    Expert Panel Validation881
  Contact Us881
  Disclaimer881
  Sources882

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Epigenetics Therapeutics to 2017 High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma" Sep 01, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Epigenetics-Therapeutics-to-2017-High-Market-Potential-for-Epigenetics-Drugs-in-Acute-Myeloid-Leukemia-Multiple-Myeloma-and-Cutaneous-T-Cell-Lymphoma-2115-78>
  
APA:
GBI Research Reports. (2010). Epigenetics Therapeutics to 2017 High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma Sep 01, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Epigenetics-Therapeutics-to-2017-High-Market-Potential-for-Epigenetics-Drugs-in-Acute-Myeloid-Leukemia-Multiple-Myeloma-and-Cutaneous-T-Cell-Lymphoma-2115-78>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.